查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954808

支原體檢測市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2026-2034 年）

Mycoplasma Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 請詢問到貨日

價格

支原體偵測市場成長驅動因素

2025 年全球支原體檢測市值為 9.723 億美元。預計到 2026 年，該市場將成長至 10.211 億美元，並在 2034 年進一步達到 15.517 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 5.40%。

北美地區在 2025 年佔市場主導地位，市佔率為 49.20%，這得益於其強大的研究基礎設施、不斷加強的監管措施以及高額的研發投入。

支原體是最小的獨立生活微生物，也是細胞培養中最常見的污染源之一。 生物製藥生產。 由於缺乏堅硬的細胞壁，它們對許多抗生素具有抗藥性，並且可以通過標準過濾系統。有鑑於此特性，實驗室、疫苗生產和生物製藥生產中必須定期進行支原體檢測，以防止污染和經濟損失。

新冠疫情的影響

由於疫苗和藥物研發中細胞培養物的儲存和檢測增加，新冠疫情對市場產生了積極影響。疫苗研發的激增促使2020年對檢測試劑盒和試劑的需求顯著增加。雖然需求在2021年趨於正常，但預計針對慢性病和傳染病的持續研發活動將支撐市場穩定成長至2034年。

市場趨勢

策略聯盟增多

診斷公司之間聯盟的增加正在推動對先進檢測技術的需求成長。 市場參與者正專注於併購和合作，以整合專業知識並強化其產品組合。旨在縮短檢測時間和提高靈敏度的技術創新正受到製藥和生物技術公司的關注。

基於PCR的檢測技術進步

基於PCR的檢測方法因其高靈敏度、特異性和快速出結果而日益普及。核酸擴增技術（NAT）的採用和監管指南的更新進一步加速了先進檢測解決方案的應用。

市場成長驅動因素

生物製藥和生技公司研發投入的增加是主要的成長驅動因素。隨著疫苗開發、細胞療法和生物製品投資的增加，對嚴格的污染控制措施的需求也隨之增加，推動了對檢測試劑盒的需求。

全球醫療保健支出的成長以及人們對細胞培養污染的日益關注也促進了市場成長。 更新的監管標準和品質控制指南正在推動實驗室和研究機構進行常規檢測。

限制因子

先進檢測試劑盒和設備的高昂成本可能會限制新興市場的採用。基於PCR的試劑盒和檢測系統需要專用設備和訓練有素的專業人員，從而增加了整體營運成本。此外，全球熟練實驗室人員的短缺可能會阻礙某些地區的市場擴張。

市場區隔分析

依產品劃分

此市場細分分為試劑和試劑盒以及儀器。

  • 由於常規檢測中的頻繁使用以及新產品的增加，試劑和試劑盒細分市場預計將在2026年佔57.85%的市場佔有率。
  • 由於新興市場滲透率的提高和技術進步，儀器細分市場預計將保持穩定成長。

依檢測方法

市場分為基於PCR、基於培養和其他方法。

  • 預計到2026年，基於PCR的檢測方法將佔56.92%的市場佔有率，主要得益於其高靈敏度、高效率和短處理時間。
  • 由於處理時間長、靈敏度低，基於培養的檢測方法預計成長率較低，但其低成本正在推動其在發展中地區的普及。

依應用

應用包括細胞培養、疫苗檢測和病毒檢測。

  • 預計到2026年，細胞培養領域將佔37.36%的市場佔有率，主要得益於日益增長的污染擔憂和不斷增加的研究活動。
  • 預計2034年，病毒檢測領域將達到最高的複合年增長率，主要得益於疫情監測的加強。
  • 疫苗測試持續受益於免疫接種計畫的擴展和研發投入的增加。

依最終使用者劃分

市場細分包括生物製藥和生物技術公司、細胞庫、合約研究組織/合約生產組織 (CRO/CMO) 以及其他公司。

  • 生物製藥和生技公司預計將以 32.99% 的市佔率領先，這主要得益於其研發管線的擴展。
  • 細胞庫預計將實現最高的複合年增長率 (CAGR)，這主要得益於對幹細胞和其他生物樣本儲存需求的不斷增長。

區域洞察

北美

北美仍然是領先的地區。 預計到2026年，該地區市場規模將達到5.032億美元，其中美國市場預計為4.596億美元。政府的大力投入和疫苗研發措施將持續推動市場需求。

歐洲

預計歐洲市場將實現溫和成長。受研發投入增加的推動，英國市場預計到2026年將達到4,930萬美元，德國市場預計到2026年將達到3,770萬美元。

亞太地區

預計到2034年，亞太地區將達到最高的複合年增長率。受生物製藥領域合作拓展與成長的推動，預計到2026年，日本市場將達到5,240萬美元，中國市場將達到4,230萬美元，印度市場將達到3,780萬美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2025年主要地區/國家研發支出概覽
  • 支原體偵測技術進展
  • 產業主要發展動態－併購與合作
  • 新產品發布
  • 新冠疫情對市場的影響

第五章：全球支原體檢測市場分析、洞察與預測 (2021-2034)

  • 市場分析、洞察與預測 - 依檢測方法劃分
    • 基於PCR的方法
    • 基於培養的方法
    • 其他方法
  • 市場分析、洞察與預測 - 依產品劃分
    • 設備
    • 試劑和試劑盒
  • 市場分析、洞察與預測 - 依應用劃分
    • 細胞培養
    • 疫苗檢測
    • 病毒檢測
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 生物製藥和生物技術公司
    • 細胞庫
    • 合約研究與生產組織
    • 其他
  • 市場分析、洞察與預測 - 依區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章 北美洲支原體檢測市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲支原體檢測市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第八章 亞太地區支原體檢測市場分析、洞察與預測2021-2034

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 其他亞太地區

第九章：全球其他地區支原體檢測市場分析、洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sartorius AG
    • Asahi Kasei Corporation
    • Biomeriux SA
    • Charles River Laboratories
    • ATCC
    • Other Prominent Players
Product Code: FBI108687

Growth Factors of mycoplasma testing Market

The global mycoplasma testing market was valued at USD 972.3 million in 2025. The market is projected to grow to USD 1,021.10 million in 2026 and further reach USD 1,551.70 million by 2034, registering a CAGR of 5.40% during the forecast period (2026-2034).

North America dominated the market with a 49.20% share in 2025, supported by strong research infrastructure, rising regulatory initiatives, and high R&D expenditure.

Mycoplasma are the smallest free-living organisms and are among the most common contaminants in cell cultures and biopharmaceutical production. Due to their lack of a rigid cell wall, they are resistant to many antibiotics and can pass through standard filtration systems. This makes routine mycoplasma testing essential in research laboratories, vaccine production, and biologics manufacturing to prevent contamination and financial losses.

COVID-19 Impact

The COVID-19 pandemic positively impacted the market due to increased storage and testing of cell cultures for vaccine and drug development. The surge in vaccine R&D significantly increased demand for testing kits and reagents in 2020. Although demand normalized in 2021, continued R&D activities for chronic diseases and infectious conditions are expected to support steady market growth through 2034.

Market Trends

Increasing Strategic Partnerships

Rising demand for advanced testing technologies has led to increased collaborations among diagnostic companies. Market players are focusing on mergers, acquisitions, and partnerships to combine expertise and enhance product portfolios. Technological advancements aimed at reducing turnaround time and improving sensitivity are gaining traction among pharmaceutical and biotechnology companies.

Technological Advancements in PCR-Based Testing

PCR-based testing methods are becoming more popular due to their high sensitivity, specificity, and faster results. Adoption of nucleic acid amplification techniques (NAT) and regulatory guideline updates are further accelerating the use of advanced testing solutions.

Market Growth Drivers

The increasing R&D expenditure among biopharmaceutical and biotechnology companies is a major driver. Growing investments in vaccine development, cell therapies, and biologics require strict contamination control measures, boosting demand for testing kits.

Rising healthcare expenditure globally and growing awareness regarding cell culture contamination are further contributing to market growth. Updated regulatory standards and quality control guidelines are encouraging routine testing in laboratories and research facilities.

Restraining Factors

High costs associated with advanced testing kits and instruments may limit adoption in emerging markets. PCR-based kits and detection systems require specialized equipment and trained professionals, increasing overall operational costs. Additionally, the shortage of skilled laboratory personnel globally may hinder market expansion in certain regions.

Segmentation Analysis

By Product

The market is segmented into reagents & kits and instruments.

  • The reagents & kits segment dominated the market with a 57.85% share in 2026, driven by their frequent usage in routine laboratory testing and rising product launches.
  • The instruments segment is expected to grow steadily due to increasing penetration in emerging markets and technological advancements.

By Testing Method

The market is categorized into PCR-based, culture-based, and others.

  • The PCR-based segment is projected to lead with a 56.92% share in 2026, owing to high sensitivity, efficiency, and shorter turnaround time.
  • The culture-based segment is expected to grow at a slower rate due to longer processing time and lower sensitivity, although its lower cost supports adoption in developing regions.

By Application

Applications include cell culture, vaccine testing, virus testing, and others.

  • The cell culture segment will account for 37.36% share in 2026, supported by rising contamination concerns and increasing research activities.
  • The virus testing segment is anticipated to register the highest CAGR through 2034 due to increasing outbreak monitoring.
  • Vaccine testing continues to benefit from growing immunization programs and R&D investments.

By End-user

The market is segmented into biopharmaceutical & biotechnology companies, cell banks, CROs & CMOs, and others.

  • The biopharmaceutical & biotechnology companies segment is projected to lead with a 32.99% share, driven by expanding R&D pipelines.
  • The cell banks segment is expected to register the highest CAGR due to growing storage of stem cells and other biological samples.

Regional Insights

North America

North America remains the dominant region. The market in the region reached USD 503.2 million in 2026, with the U.S. market estimated at USD 459.6 million in 2026. Strong government funding and vaccine development initiatives continue to drive demand.

Europe

Europe is expected to grow at a moderate rate. The UK market is projected to reach USD 49.3 million by 2026, while Germany is estimated at USD 37.7 million in 2026, supported by rising R&D investments.

Asia Pacific

Asia Pacific is projected to register the highest CAGR through 2034. Japan is estimated to reach USD 52.4 million by 2026, China USD 42.3 million, and India USD 37.8 million, driven by increasing collaborations and expanding biopharmaceutical sectors.

Competitive Landscape

The market is fragmented, with key players including Merck KGaA, Thermo Fisher Scientific Inc., Lonza, F. Hoffmann-La Roche Ltd., Sartorius AG, bioMerieux SA, and Asahi Kasei Corporation.

Companies are focusing on technological innovation, product launches, partnerships, and facility expansions to strengthen their global presence. Strategic initiatives and R&D investments are expected to intensify competition through 2034.

Conclusion

The global mycoplasma testing market is projected to grow from USD 972.3 million in 2025 to USD 1,551.70 million by 2034, driven by rising R&D activities, increasing contamination concerns, and technological advancements in PCR-based testing. While high costs and skilled workforce shortages may restrain growth in emerging markets, expanding vaccine production, biologics development, and regulatory compliance requirements will sustain long-term market expansion. North America will continue to dominate, while Asia Pacific is expected to witness the fastest growth through 2034.

Segmentation By Testing Method

  • PCR-based
  • Culture-based
  • Others

By Product

  • Instruments
  • Reagents & Kits

By Application

  • Cell Culture
  • Vaccine Testing
  • Virus Testing
  • Others

By End-user

  • Biopharmaceutical & Biotechnology Companies
  • Cell banks
  • Contract Research Organizations & Contract Manufacturing Organizations
  • Others

By Region

  • North America (By Testing Method, Product, Application, End-user, and By Country)
    • U.S. (By Testing Method)
    • Canada (By Testing Method)
  • Europe (By Testing Method, Product, Application, End-user, and Country/Sub-region)
    • U.K. (By Testing Method)
    • Germany (By Testing Method)
    • France (By Testing Method)
    • Italy (By Testing Method)
    • Spain (By Testing Method)
    • Rest of Europe (By Testing Method)
  • Asia Pacific (By Testing Method, Product, Application, End-user, and Country/Sub-region)
    • China (By Testing Method)
    • Japan (By Testing Method)
    • India (By Testing Method)
    • Australia (By Testing Method)
    • Southeast Asia (By Testing Method)
    • Rest of Asia Pacific (By Testing Method)
  • Rest of the World (By Testing Method, Product, Application, and End-user)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of R&D Expenditure, Key Regions/Key Countries, 2025
  • 4.2. Technological Advancements in Mycoplasma Testing
  • 4.3. Key Industry Developments - Mergers, Acquisitions & Partnership
  • 4.4. New Product Launches
  • 4.5. Impact of COVID-19 on the Market

5. Global Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Testing Method
    • 5.1.1. PCR-based
    • 5.1.2. Culture-based
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Instruments
    • 5.2.2. Reagents & Kits
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Cell Culture
    • 5.3.2. Vaccine Testing
    • 5.3.3. Virus Testing
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Biopharmaceutical & Biotechnology Companies
    • 5.4.2. Cell banks
    • 5.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Testing Method
    • 6.1.1. PCR-based
    • 6.1.2. Culture-based
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Instruments
    • 6.2.2. Reagents & Kits
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Cell Culture
    • 6.3.2. Vaccine Testing
    • 6.3.3. Virus Testing
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Biopharmaceutical & Biotechnology Companies
    • 6.4.2. Cell banks
    • 6.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 6.5.1. U.S.
      • 6.5.1.1. By Testing Method
    • 6.5.2. Canada
      • 6.5.2.1. By Testing Method

7. Europe Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Testing Method
    • 7.1.1. PCR-based
    • 7.1.2. Culture-based
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Instruments
    • 7.2.2. Reagents & Kits
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Cell Culture
    • 7.3.2. Vaccine Testing
    • 7.3.3. Virus Testing
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Biopharmaceutical & Biotechnology Companies
    • 7.4.2. Cell banks
    • 7.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K
      • 7.5.1.1. By Testing Method
    • 7.5.2. Germany
      • 7.5.2.1. By Testing Method
    • 7.5.3. France
      • 7.5.3.1. By Testing Method
    • 7.5.4. Spain
      • 7.5.4.1. By Testing Method
    • 7.5.5. Italy
      • 7.5.5.1. By Testing Method
    • 7.5.6. Rest of Europe
      • 7.5.6.1. By Testing Method

8. Asia Pacific Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Testing Method
    • 8.1.1. PCR-based
    • 8.1.2. Culture-based
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Instruments
    • 8.2.2. Reagents & Kits
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Cell Culture
    • 8.3.2. Vaccine Testing
    • 8.3.3. Virus Testing
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Biopharmaceutical & Biotechnology Companies
    • 8.4.2. Cell banks
    • 8.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
      • 8.5.1.1. By Testing Method
    • 8.5.2. China
      • 8.5.2.1. By Testing Method
    • 8.5.3. India
      • 8.5.3.1. By Testing Method
    • 8.5.4. Australia
      • 8.5.4.1. By Testing Method
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Testing Method
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Testing Method

9. Rest of the World Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Testing Method
    • 9.1.1. PCR-based
    • 9.1.2. Culture-based
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Instruments
    • 9.2.2. Reagents & Kits
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Cell Culture
    • 9.3.2. Vaccine Testing
    • 9.3.3. Virus Testing
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Biopharmaceutical & Biotechnology Companies
    • 9.4.2. Cell banks
    • 9.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 9.4.4. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Merck KGaA
      • 10.2.1.1. Overview
      • 10.2.1.2. Product
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. Thermo Fisher Scientific Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Product
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. F. Hoffmann-La Roche Ltd.
      • 10.2.3.1. Overview
      • 10.2.3.2. Product
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. Sartorius AG
      • 10.2.4.1. Overview
      • 10.2.4.2. Product
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. Asahi Kasei Corporation
      • 10.2.5.1. Overview
      • 10.2.5.2. Product
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. Biomeriux SA
      • 10.2.6.1. Overview
      • 10.2.6.2. Product
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. Charles River Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Product
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. ATCC
      • 10.2.8.1. Overview
      • 10.2.8.2. Product
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. Other Prominent Players

List of Tables

  • Table 1: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 2: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 3: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 4: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 5: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 6: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 7: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 8: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 9: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 10: North America Mycoplasma Testing Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 11: U.S. Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 12: Canada Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 13: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 14: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 15: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 16: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 17: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: U.K. Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 19: Germany Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 20: France Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 21: Italy Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 22: Spain Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 23: Rest of Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 24: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 25: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 26: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 27: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: China Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 30: Japan Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 31: India Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 32: Australia Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 33: Southeast Asia Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 34: Rest of Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 35: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 36: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 37: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 38: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Mycoplasma Testing Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Mycoplasma Testing Market Value Share (%), by Testing Method, 2025 & 2034
  • Figure 3: Global Mycoplasma Testing Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Mycoplasma Testing Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Mycoplasma Testing Market Value Share (%), by End-user, 2025 & 2034
  • Figure 6: Global Mycoplasma Testing Market Value (USD million), by Region, 2025 & 2034
  • Figure 7: North America Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 8: North America Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 9: North America Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 10: North America Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 11: North America Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 12: North America Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 13: North America Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 14: North America Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 15: North America Mycoplasma Testing Market Value (USD million), By Country, 2025 & 2034
  • Figure 16: North America Mycoplasma Testing Market Value Share (%), By Country, 2025
  • Figure 17: Europe Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 18: Europe Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 19: Europe Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 20: Europe Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 21: Europe Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 22: Europe Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 23: Europe Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 24: Europe Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 25: Europe Mycoplasma Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Mycoplasma Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 28: Asia Pacific Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 29: Asia Pacific Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 30: Asia Pacific Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 31: Asia Pacific Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Asia Pacific Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 33: Asia Pacific Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 34: Asia Pacific Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 35: Asia Pacific Mycoplasma Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Mycoplasma Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of the World Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 38: Rest of the World Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 39: Rest of the World Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 40: Rest of the World Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 41: Rest of the World Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 42: Rest of the World Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 43: Rest of the World Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 44: Rest of the World Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 45: Global Mycoplasma Testing Market Share (%), By Company, 2025